Lanzopral: Medical Uses, Administration, Side Effects, Precautions and Interactions

Sold under the brand name Prevacid among others, it is a drug that inhibits stomach acid production.

There is no evidence that its effectiveness is different from that of other proton pump inhibitors (PPIs).

Lanzopral, administered through a nasogastric tube, effectively controls the pH within the stomach and is an alternative to intravenous pantoprazole in people who cannot swallow solid-dose formulations.

Lanzopral is a proton pump inhibitor in the same pharmacological class as omeprazole. Lanzopral has been around for many years and is one of several proton pump inhibitors available.

It is a 1: 1 racemic mixture of the enantiomers dexLanzopral (Dexilant, formerly called Kapidex) and levolanzopral. Dexlanzopral is an enantiomerically pure active ingredient of a commercial drug as a result of enantiomeric change.

The plasma elimination half-life of Lanzopral (1.5 hours) is not proportional to the duration of the drug’s effects in the person (ie gastric acid suppression). The effects of the medicine last more than 24 hours after it has been used for a day or more.

Lanzopral is a white to brownish-white odorless crystalline powder that melts on decomposition at approximately 166 ° C.

Lanzopral is freely soluble in dimethylformamide; soluble in methanol; sparingly soluble in ethanol; slightly soluble in ethyl acetate, dichloromethane, and acetonitrile; very slightly soluble in ether; and practically insoluble in hexane and water.

Lanzopral is stable when exposed to light for up to two months. The degradation rate of the compound in aqueous solution increases with decreasing pH.

The degradation half-life of the drug substance in aqueous solution at 25 ° C is approximately 0.5 hours at pH 5.0 and approximately 18 hours at pH 7.0.

Lanzopral is supplied in delayed-release capsules and is supplied in oral delayed-release tablets for oral administration.

It is manufactured by various companies around the world under various brand names. In the United States, it was first approved by the Food and Drug Administration (FDA) in 1995. Prevacid’s patent protection expired on November 10, 2009.

Medical uses

Lanzopral is used to treat:

Ulcers of the stomach and duodenum, and non-steroidal anti-inflammatory drugs (NSAIDs).

Helicobacter pylori infection, along with antibiotics (adjuvant treatment), treatment to kill H. pylori that causes ulcers or other problems involves the use of two other drugs in addition to Lanzopral known as ‘triple therapy’, and involves taking twice a day for 10 or 14 days Lanzopral, amoxicillin, and clarithromycin

Gastroesophageal reflux disease. Zollinger-Ellison syndrome.

There is no good evidence that it works better than other proton pump inhibitors.

Lanzopral Administration

Do not crush or chew the capsules. Swallow the medication whole. If you have trouble swallowing the capsule, you can open the capsule and sprinkle its contents on a tablespoon of soft foods (such as applesauce, cottage cheese, yogurt) and swallow the mixture immediately without chewing.

Or you can pour the contents of the capsule into a small amount (2 ounces or 60 milliliters) of juice, mix and drink the mixture immediately without chewing. Then rinse the glass with more juice and drink to make sure you have taken the full dose.

If you are giving this medicine through a tube into your stomach (nasogastric tube), ask your healthcare professional for detailed instructions on how to mix and give it.

Keep taking this medicine for the prescribed time of treatment, even if you feel better. If you self-medicate with the OTC product, do not take it for more than 14 days, unless directed by your doctor. The risk of side effects increases over time.

Side effects

Side effects of proton pump inhibitors in general and Lanzopral in particular can include:

Common : may cause diarrhea, abdominal pain or headache.

Uncommon : dry mouth, insomnia, drowsiness, blurred vision, rash, itching.

Rarely : taste disturbance, liver dysfunction, peripheral edema, hypersensitivity reactions (including bronchospasm, urinary tract, angioedema, anaphylaxis), photosensitivity, fever, sweating, depression, interstitial nephritis.

Blood disorders (including leukopenia, leukocytosis, pancytopenia, thrombocytopenia), arthralgia, myalgia, skin reactions including (Stevens-Johnson syndrome erythroderma, toxic epidermal necrolysis, bullous rash).

Proton pump inhibitors may be associated with an increased risk of hip fractures and Clostridium difficile-associated diarrhea.

Precautions

Before taking Lanzopral, tell your doctor or pharmacist if you are allergic to it; or to similar medicines (such as dexLanzopral, omeprazole, pantoprazole); or if you have any other allergies.

This product may contain inactive ingredients, which can cause allergic reactions or other problems, and get medical attention immediately if you have:

Heartburn with feeling dizzy / sweating, chest / jaw / arm / shoulder pain (especially with shortness of breath, unusual sweating), unexplained weight loss.

Lanzopral and proton pump inhibitors can develop your risk of bone fractures, especially with long-term use, higher doses, and in older adults.

Talk to your doctor or pharmacist about ways to prevent bone loss / fracture, such as taking calcium (such as calcium citrate) and vitamin D supplements.

Interactions

Lanzopral interacts with other medications, either by its own nature or as proton pump inhibitors.

The proton pump inhibitor reduces the absorption of antifungals (itraconazole and ketoconazole) and possibly increases plasma digoxin. Increases plasma concentrations of cilostazol (risk of toxicity).

Lanzopral possibly interacts with, among other drugs:

  • Sucralfato.
  • Ampicillin.
  • Bisacodilo.
  • Clopidogrel.
  • Delavirdine.
  • Fluvoxamina.
  • Iron salts.
  • Voriconazole.
  • Aminophylline and theophylline.
  • Astemizole.

History

Lanzopral was originally synthesized at Takeda and was given the development name AG 1749. It was patented by Takeda in 1984 and the drug was released in 1991.

In the late 1970s, evidence emerged that the newly discovered proton pump (H + / K + ATPase) in the secretory membrane of the parietal cell was the final step in acid secretion.

The anesthesia test literature drew attention to the potential antiviral compound pyridylthioacetamide which, upon further examination, pointed to an antisecretory compound with unknown mechanisms of action called thymoprazole.

Thimoprazole is a pyridylmethylsulfinylbenzimidazole and attractive due to its simple chemical structure and surprisingly high level of antisecretory activity.

The optimization of substituted benzimidazoles and their antisecretory effects were studied in the recently discovered proton pump to obtain higher values ​​of pyridine pKa, thus facilitating accumulation within the parietal cell and increasing the rate of acid-mediated conversion to active mediate. .

As a result of this optimization, the first proton pump inhibitor drug, omeprazole, was launched on the market.

Other proton pump inhibitors such as Lanzopral and pantoprazole would follow in their footsteps, reclaiming their share of a burgeoning market, after their own course of development.

Society and culture

Patents

The Lanzopral molecule is patent-free and therefore generic drugs are available under many brand names in many countries; There are patents that cover some formulations effective as of 2015.

Availability

Since 2009, Lanzopral has been available over the counter (OTC) in the US in a product marketed by Novartis as Prevacid 24HR.

In Australia, it is marketed by Pfizer as Zoton.

Investigation

In vitro experiments have shown that Lanzopral binds to the pathogenic form of the tau protein.

As of 2015, laboratory studies on Lanzopral analogs were underway to explore their use as potential positron emission tomography (PET) imaging agents for the diagnosis of tauopathies, including the disease. Alzheimer’s.

Lanzopral is also a prodrug that targets the cytochrome bc1 complex of mycobacterial tuberculosis once converted to Lanzopral sulfide in mycobacterial host cells.